调控肠道菌群：增强 PD-1 和 PD-L1 阻断治疗疗效的新策略。
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
机构信息
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
出版信息
Front Immunol. 2018 Mar 5;9:374. doi: 10.3389/fimmu.2018.00374. eCollection 2018.
Blockade of programmed death 1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) has been used as cancer immunotherapy in recent years, with the blockade of PD-1 being more widely used than blockade of PD-L1. PD-1 and PD-L1 blockade therapy showed benefits in patients with various types of cancer; however, such beneficial effects were seen only in a subgroup of patients. Improving the efficacy of PD-1 and PD-L1 blockade therapy is clearly needed. In this review, we summarize the recent studies on the effects of gut microbiota on PD-1 and PD-L1 blockade and discuss the new perspectives on improving efficacy of PD-1 and PD-L1 blockade therapy in cancer treatment through modulating gut microbiota. We also discuss the possibility that chronic infections or inflammation may impact on PD-1 and PD-L1 blockade therapy.
近年来，程序性死亡受体 1（PD-1）蛋白及其配体程序性死亡配体 1（PD-L1）的阻断已被用于癌症免疫治疗，其中 PD-1 的阻断比 PD-L1 的阻断应用更为广泛。PD-1 和 PD-L1 阻断疗法在各种类型的癌症患者中均显示出获益，但这种有益作用仅见于部分患者。显然需要提高 PD-1 和 PD-L1 阻断疗法的疗效。在这篇综述中，我们总结了肠道微生物群对 PD-1 和 PD-L1 阻断作用的最新研究，并讨论了通过调节肠道微生物群改善 PD-1 和 PD-L1 阻断疗法在癌症治疗中的疗效的新观点。我们还讨论了慢性感染或炎症是否可能影响 PD-1 和 PD-L1 阻断疗法的可能性。
Zotero 插件